» Articles » PMID: 37080422

Maternal Vaccination to Prevent Adverse Pregnancy Outcomes: An Underutilized Molecular Immunological Intervention?

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2023 Apr 20
PMID 37080422
Authors
Affiliations
Soon will be listed here.
Abstract

Adverse pregnancy outcomes including maternal mortality, stillbirth, preterm birth, intrauterine growth restriction cause millions of deaths each year. More effective interventions are urgently needed. Maternal immunization could be one such intervention protecting the mother and newborn from infection through its pathogen-specific effects. However, many adverse pregnancy outcomes are not directly linked to the infectious pathogens targeted by existing maternal vaccines but rather are linked to pathological inflammation unfolding during pregnancy. The underlying pathogenesis driving such unfavourable outcomes have only partially been elucidated but appear to relate to altered immune regulation by innate as well as adaptive immune responses, ultimately leading to aberrant maternal immune activation. Maternal immunization, like all immunization, impacts the immune system beyond pathogen-specific immunity. This raises the possibility that maternal vaccination could potentially be utilised as a pathogen-agnostic immune modulatory intervention to redirect abnormal immune trajectories towards a more favourable phenotype providing pregnancy protection. In this review we describe the epidemiological evidence surrounding this hypothesis, along with the mechanistic plausibility and present a possible path forward to accelerate addressing the urgent need of adverse pregnancy outcomes.

Citing Articles

Evaluating the Efficacy and Safety of Hepatitis E Vaccination in Reproductive-Age Women: A Systematic Review and Meta-Analysis.

Jotautis V, Sarantaki A Vaccines (Basel). 2025; 13(1).

PMID: 39852832 PMC: 11768898. DOI: 10.3390/vaccines13010053.


The mark of success: The role of vaccine-induced skin scar formation for BCG and smallpox vaccine-associated clinical benefits.

Baek O, Schaltz-Buchholzer F, Campbell A, Amenyogbe N, Campbell J, Aaby P Semin Immunopathol. 2024; 46(5):13.

PMID: 39186134 PMC: 11347488. DOI: 10.1007/s00281-024-01022-9.


Potential Cost-Effectiveness of Maternal Influenza Immunisation in Low-Income Countries: An Explorative Modelling Study and Value of Information Analysis to Guide Future Clinical Research.

Wang Y, Giles M, Carvalho N Vaccines (Basel). 2024; 12(3).

PMID: 38543866 PMC: 10975179. DOI: 10.3390/vaccines12030232.

References
1.
Andersen A, Kolmos S, Flanagan K, Benn C . Systematic review and meta-analysis of the effect of pertussis vaccine in pregnancy on the risk of chorioamnionitis, non-pertussis infectious diseases and other adverse pregnancy outcomes. Vaccine. 2021; 40(11):1572-1582. DOI: 10.1016/j.vaccine.2021.02.018. View

2.
Marchant A, Sadarangani M, Garand M, Dauby N, Verhasselt V, Pereira L . Maternal immunisation: collaborating with mother nature. Lancet Infect Dis. 2017; 17(7):e197-e208. DOI: 10.1016/S1473-3099(17)30229-3. View

3.
Huhn O, Ivarsson M, Gardner L, Hollinshead M, Stinchcombe J, Chen P . Distinctive phenotypes and functions of innate lymphoid cells in human decidua during early pregnancy. Nat Commun. 2020; 11(1):381. PMC: 6971012. DOI: 10.1038/s41467-019-14123-z. View

4.
Heikkinen T, Young J, van Beek E, Franke H, Verstraeten T, Weil J . Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol. 2012; 207(3):177.e1-8. DOI: 10.1016/j.ajog.2012.07.007. View

5.
Beigi R, Krubiner C, Jamieson D, Lyerly A, Hughes B, Riley L . The need for inclusion of pregnant women in COVID-19 vaccine trials. Vaccine. 2021; 39(6):868-870. PMC: 7798437. DOI: 10.1016/j.vaccine.2020.12.074. View